VisEn Medical has launched a new fluorescence agent for imaging gastric motility and related drug effects in vivo. 

The company said its new GastroSense 750 fluorescence imaging agent is designed to enable quantitative measurements of gastric motility in animal models, thereby enabling assessment of various related diseases and drug effects in preclinical research and drug development. 

The Bedford, Mass.-based VisEn's technologies are designed to generate translational data linking preclinical research into clinical medicine.